Project Grant R21AI190782
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$239K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,208,700 to the University of California, San Diego (UCSD) to develop a prototype assay for detecting active tuberculosis (TB) disease in people living with HIV. The key products and services to be delivered through this 2-year project include: Determining the analytical performance of the prototype assay by...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $727,273 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop a microfluidic multiplexed antibody profiling chip and point-of-care detection microchip for rapid and scalable diagnosis of tuberculosis (TB). The goal is to leverage machine learning to define antibody signatures that can differentiate active TB disease from latent TB infection,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000.00 to Salus Discovery LLC, a for-profit limited liability company, to develop a next-generation urine-based lateral flow assay (LFA) for tuberculosis (TB) diagnosis in point-of-care settings. The primary goal of this award is to address the critical gap in access to high-quality TB testing, as identified by...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will enable the development and evaluation of enhanced swab sampling methods for high-sensitivity tongue swab testing to diagnose active tuberculosis (TB). The $944,663 award will fund research to: 1) Develop and assess high-capacity oral swab testing for pulmonary TB, and 2) Develop and assess protocols for testing serially...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $838,989 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to conduct comprehensive characterization of RV0678 mutations conferring bedaquiline resistance in Mycobacterium tuberculosis. The goal is to develop an accurate molecular diagnostic test to rapidly detect bedaquiline resistance and inform treatment decisions, regardless...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
The federal Project Grant award R44AI179588, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of Salus Discovery LLC's 3STEP platform - a swab-seal-read assay for the detection of tuberculosis (TB) and rifampicin resistance. The $295,893 award, with a period of performance from June 2024 to May 2025, aims to advance an affordable point-of-care (POC) nucleic acid testing...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $517,185 award, with a performance period from August 1, 2024 to June 30, 2026, will fund research to characterize the immune response to tuberculosis (TB) using integrated single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will generate multi-omic data, including...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,011,348 to the Texas Biomedical Research Institute over a 5-year period starting August 2024. The research project aims to investigate the early interactions between the tuberculosis bacterium (M.TB) and the human alveolar environment, particularly how exposure to the alveolar lining fluid (ALF) from people...